After obtaining the approval of the institutional ethics committee (Sri Siddhartha Medical College, Siddhartha Academy of Higher Education) and informed consent from patients, 100 patients aged 18 - 60 years posted for lower limb orthopedic surgery were selected for the study. A detailed history, thorough clinical examination, and routine investigations were carried out.
3.2. Exclusion Criteria
The exclusion criteria were cardiac, respiratory, or central nervous system disorders, hepatic and renal dysfunction, bleeding diathesis, history of allergy to local anesthetics, contraindication to spinal and epidural anesthesia, complex pain syndrome, and using opioids.
The patients were advised to have an overnight fast of 8 hours for solid food. On arrival to the operating room, the IV line was secured with an 18-gauge cannula under aseptic precaution and ringer lactate solution infused at 10 - 20 mL/kg. The patients were allocated by computer-generated randomization into group A, receiving bupivacaine (anawin 0.5%, Neon Laboratories, Mumbai, India) with buprenorphine (buprigesic 0.3 mg, Neon Laboratories, Mumbai, India), and group B, receiving bupivacaine and butorphanol (butodol 2 mg, Neon Laboratories, Mumbai, India) epidurally. Under all aseptic precautions, an 18 G Tuohy needle (B Braun Prefix epidural set, Curit Pharmaceuticals, Ahmedabad, India) was introduced into L2 - L3 interspace, epidural space identified by the method of loss of resistance technique for air. Lignocaine 2% with epinephrine (1: 200000) (3 mL) was injected after securing the epidural catheter as a test dose. A 27-gauge Quincke needle (Bectan, Dickinson India Pvt Ltd., Chennai, India) was introduced at the L3 - L4 intervertebral space, and 3.4 mL of bupivacaine 0.5% heavy (anawin 0.5% hyperbaric, Neon Laboratories, Mumbai, India) was injected into subarachnoid space after confirming the backflow of cerebrospinal fluid. Intraoperative heart rate, blood pressure, oxygen saturation, and electrocardiogram were monitored throughout the procedure.
An anesthesiologist who was not part of the study was involved in the administration of the local anesthetics and opioids through the epidural catheter when the patient complained of pain [the visual analog scale (VAS) > 4]. The study drugs were prepared by a different anesthesiologist who was not part of the study. Therefore, the patients and the anesthesiologist, who administered the drugs and collected the data in the postoperative period, were blinded to the study design. Accordingly, double-blinding was achieved throughout the study.
Following the surgical procedure, the patient was shifted to the postoperative ward, and when the patient complained of pain (VAS > 4), the study drug was administered through the epidural catheter. Group A received 10 mL bupivacaine 0.125% with 0.3 mg buprenorphine. Group B received 10 mL bupivacaine 0.125% with 2 mg butorphanol. The patients were taught to read the VAS the night before the surgery.
Pain monitoring was assessed using the VAS, with 0, 1 - 3, 4 - 7, and 8 - 10 scores indicative of no, mild, moderate, and severe pain, respectively. Sedation was assessed by Ramsay sedation scores of 1, 2, 3, 4, 5, and 6, indicative of anxious and agitated, cooperative/oriented/tranquil, asleep and responding to verbal command, asleep but brisk response to light stimulus, sluggish response to a painful stimulus, and asleep without response to a painful stimulus, respectively. The pain was monitored after 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 10 hours, 12 hours, 16 hours, 20 hours, and 24 hours in the postoperative recovery room. The patient’s sleep was not disturbed if the patient did not complain of pain. The IV diclofenac sodium 75 mg mixed in 100 mL normal saline was started if the patient complained of pain despite receiving epidural opioids. This procedure was used as rescue analgesia. The onset of analgesia (VAS < 4, time from the injection of study medication to the first reduction in pain intensity to almost complete relief of pain) and duration of analgesia (time from epidural injection to the time of request for additional analgesia and VAS > 4) was assessed. The injection of diclofenac sodium aqueous mixed with 100 mL of normal saline was started after 24 hours of the study as analgesia.
The patients were monitored for any side effects, such as respiratory depression, nausea, vomiting, and pruritus. The study subjects were monitored for hypotension (i.e., a decrease in systolic blood pressure > 20% of the baseline value or systolic blood pressure < 90 mmHg), bradycardia (i.e., a pulse rate < 60 beats per minute treated with IV atropine 0.6 mg), and respiratory depression (i.e., a respiratory rate less than 8 breaths per minute or saturation <95% treated with O2 supplementation and respiratory support if needed).